Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis.

Literature DB >> 19851772

A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis.

Anna Rita Giardina¹, Angelo Ferrante, Francesco Ciccia, Rosalia Impastato, Maria Concetta Miceli, Alfonso Principato, Giovanni Triolo.

Abstract

The signs and symptoms of ankylosing spondylitis (AS) respond inadequately to nonsteroidal antiinflammatory drugs, corticosteroids, and disease modifying antirheumatic drugs in quite a number of patients. Tumor necrosis factor inhibitors have demonstrated to be of value in reducing AS disease activity in clinical trials. The efficacy and safety of both etanercept and infliximab in patients with ankylosing spondylitis were compared in a 2-year open label randomised study. Our results are consistent with a significant more rapid clinical improvement in the infliximab treated group. Treatment with both etanercept and infliximab at the end of the study was effective, safe, and well tolerated.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2009 PMID： 19851772 DOI： 10.1007/s00296-009-1157-3

Source DB: PubMed Journal: Rheumatol Int ISSN： 0172-8172 Impact factor: 2.631

19 in total

1. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study.

Authors: Jürgen Braun; Robert Landewé; Kay-Geert A Hermann; John Han; Songkai Yan; Paul Williamson; Désirée van der Heijde
Journal: Arthritis Rheum Date: 2006-05

Review 2. Cytokine gene polymorphisms relevant for the spondyloarthropathies.

Authors: M Rudwaleit; T Höhler
Journal: Curr Opin Rheumatol Date: 2001-07 Impact factor: 5.006

3. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria.

Authors: S van der Linden; H A Valkenburg; A Cats
Journal: Arthritis Rheum Date: 1984-04

4. Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study.

Authors: H Marzo-Ortega; D McGonagle; S Jarrett; G Haugeberg; E Hensor; P O'connor; A L Tan; P G Conaghan; A Greenstein; P Emery
Journal: Ann Rheum Dis Date: 2005-04-13 Impact factor: 19.103

5. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis.

Authors: J J Anderson; G Baron; D van der Heijde; D T Felson; M Dougados
Journal: Arthritis Rheum Date: 2001-08

Review 6. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel.

Authors: Marc C Hochberg; Mark G Lebwohl; Scott E Plevy; Kathryn F Hobbs; David E Yocum
Journal: Semin Arthritis Rheum Date: 2005-06 Impact factor: 5.532

7. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).

Authors: Désirée van der Heijde; Ben Dijkmans; Piet Geusens; Joachim Sieper; Kimberly DeWoody; Paul Williamson; Jürgen Braun
Journal: Arthritis Rheum Date: 2005-02

8. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.

Authors: John C Davis; Désirée Van Der Heijde; Jurgen Braun; Maxime Dougados; John Cush; Daniel O Clegg; Alan Kivitz; Roy Fleischmann; Robert Inman; Wayne Tsuji
Journal: Arthritis Rheum Date: 2003-11

9. Evaluation of ankylosing spondylitis spinal mobility measurements in the assessment of spinal involvement in psoriatic arthritis.

Authors: José Luis Fernández-Sueiro; Alfredo Willisch; Sonia Pértega-Díaz; José Antonio Pinto Tasende; Carlos Fernández-Lopez; Fausto Galdo; Francisco Javier Blanco
Journal: Arthritis Rheum Date: 2009-03-15

10. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.

Authors: J Brandt; A Khariouzov; J Listing; H Haibel; H Sörensen; L Grassnickel; M Rudwaleit; J Sieper; J Braun
Journal: Arthritis Rheum Date: 2003-06

20 in total

1. [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 8.4 Pharmaceutical therapy, 8.5 Evaluation of therapy success of pharmaceutical measures].

Authors: U Kiltz; J Sieper; H Kellner; D Krause; M Rudwaleit; J-F Chenot; A Stallmach; S Jaresch; J Braun
Journal: Z Rheumatol Date: 2014-09 Impact factor: 1.372

2. Thalidomide reduces recurrence of ankylosing spondylitis in patients following discontinuation of etanercept.

Authors: Xiaohu Deng; Jianglin Zhang; Jie Zhang; Feng Huang
Journal: Rheumatol Int Date: 2012-11-11 Impact factor: 2.631

3. The use of low-dose etanercept as an alternative therapy for treatment of ankylosing spondylitis: a case series.

Authors: Jamileh Moghimi; Mehrdad Sheikhvatan; Vahid Semnani
Journal: Rheumatol Int Date: 2011-05-08 Impact factor: 2.631

Review 4. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.

Authors: Michael M Ward; Atul Deodhar; Lianne S Gensler; Maureen Dubreuil; David Yu; Muhammad Asim Khan; Nigil Haroon; David Borenstein; Runsheng Wang; Ann Biehl; Meika A Fang; Grant Louie; Vikas Majithia; Bernard Ng; Rosemary Bigham; Michael Pianin; Amit Aakash Shah; Nancy Sullivan; Marat Turgunbaev; Jeff Oristaglio; Amy Turner; Walter P Maksymowych; Liron Caplan
Journal: Arthritis Care Res (Hoboken) Date: 2019-08-21 Impact factor: 4.794

Review 5. Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis.

Authors: Marina Amaral de Ávila Machado; Mariana Michel Barbosa; Alessandra Maciel Almeida; Vânia Eloisa de Araújo; Adriana Maria Kakehasi; Eli Iola Gurgel Andrade; Mariangela Leal Cherchiglia; Francisco de Assis Acurcio
Journal: Rheumatol Int Date: 2013-05-18 Impact factor: 2.631

Review 6. Etanercept: a review of its use in autoimmune inflammatory diseases.

Authors: Lesley J Scott
Journal: Drugs Date: 2014-08 Impact factor: 9.546

Review 7. Different roles of TNF inhibitors in acute anterior uveitis associated with ankylosing spondylitis: state of the art.

Authors: Claudia Fabiani; Antonio Vitale; Giuseppe Lopalco; Florenzo Iannone; Bruno Frediani; Luca Cantarini
Journal: Clin Rheumatol Date: 2016-09-30 Impact factor: 2.980

Review 8. Infliximab: 12 years of experience.

Authors: Josef S Smolen; Paul Emery
Journal: Arthritis Res Ther Date: 2011-05-25 Impact factor: 5.156

9. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.

10. Incidence of anterior uveitis in patients with axial spondyloarthritis treated with anti-TNF or anti-IL17A: a systematic review, a pairwise and network meta-analysis of randomized controlled trials.

Authors: Damien Roche; Martin Badard; Laurent Boyer; Pierre Lafforgue; Thao Pham
Journal: Arthritis Res Ther Date: 2021-07-16 Impact factor: 5.156